RE:RE:RE:New interview with TLT Investor Relations - Michael BorovecIt's not ME that's getting ahead of himself! These are Borovec's words.
"Theralase is planning to up-list to the OTCQB board in the next few months, while we move forward towards our goal of a successful NASDAQ up-list within the next 12 months."
If you think the SP is going to be $3.00 in a year, well I hope you're right. I just don't see it.
Hence, a rollback. It's inevitable.
newdaydawning wrote: I think you are getting way too far ahead of yourself with the talk of a rollback to meet NASDAQ listing rules.
TLT's first order of business is to secure another a round of financing from U.S. investors. That money will be needed for phase 2b. By that time, the SP should be sufficient to qualify for the NASDAQ, IMHO. GLTA
BeenHereBefore wrote: Great interview, but the planned NASDAQ uplisting foretells a future consolidation to meet the minimum listing requirements.
Hopefully, the TLC-2000 gets approved and revenues pick up substantially by then so the rollback is at most 3 to 1. Of course, approval of the CTA and progress with the human trials would help as well. Anyone who responds that the company will organically grow to $2 or $3 per share by then and will not need to do a share rollback is delusional. That almost never happens in the real world.
Also, I know the company recently "cashed-up" from the $8 Million private placement, but it also seems like Borovec was hinting at other possible future financings:
"We have recently participated in investor meetings in the United States, meeting with a number of financial institutions who own or have an interest in owning Theralase stock."
Hopefully, they don't further dilute us too much then announce a 10 to 1 rollback.
All that gloom and doom said, I have been long TLT for almost two years and am rightly optimistic that the future is bright. But I'm also a realist and know that corporate finance is a game of sharks who rarely care very much about the retail shareholder.